Current evidence suggests that optimizing the GLP-1 dose typically achieves better outcomes than adding a second incretinotropic agent
Common Misconceptions Future Research Directions Useful future work would include independently replicated receptor studies, validated analytical and potency methods, formulation and stability research, broader pharmacokinetic characterization, formal toxicology, endocrine and metabolic safety assessment, interaction studies, and adequately powered controlled clinical trials
Low-density lipoprotein metabolism in rats treated with cyclosporine
10.1007/s12015-024-10840-1 42 YinY.HaoH.ChengY.ZangL.LiuJ.GaoJ.et al (2018)
CoQ10 bioavailability varies substantially by formulation, which may partly explain inconsistent behavioral findings across trials
We had missing participant data ( n = 2 (GLP-1RA group) and n = 3 (Control group) for TLFB which is denoted by an asterisk in Table 1